AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...
Investors in Genmab A/S GMAB need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $17.50 Call had some of the highest implied volatility...
Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...
AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.ABBV...
There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...
The biotech stock's lead therapy is looking at some competition.
Zai Lab's shares benefited from positive clinical trial news.
Find out if AbbVie can overcome sinking sales of its top-selling product.
The company has been a strong value stock but faces big changes this year.
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.